a benign bile duct proliferation within well-vascularized fibrous tissue consistent with mesenchymal hamartoma, with bile duct hamartomas (von Meyenberg complexes) in adjacent hepatic parenchyma. Six months later the patient's WBC was 32 800/l, Hgb 8.7 g/dl and platelets 415 000/l.
The patient was assessed by cytogenetic analysis and was found to be diploid (20 of 20 cells). Likewise, fluorescent in situ hybridization (FISH) analysis (of 500 cells) detected no BCR-ABL fusion events. In addition, no studies were done to search for TEL-ABL fusion events. However, analysis of peripheral white blood cells by anti-Abl Western blotting revealed a 170 kDa Abl-related protein ( Figure 1a, lane 3) . In all cases a protein the size of P145 ABL (the normal cellular ABL gene product) was also detected. The 170 kDa Abl-related protein had a faster mobility than authentic P190 BCR-ABL from a Ph-positive ALL patient ( Figure 1a , lane 2). Comparing the mobility of authentic molecular weight standards (Cat. No. 082400 and 102000; Diversified Biotech, Boston, MA, USA) to the mobility of this protein indicated that it had an estimated molecular weight of 170 kDa. Examination of blots with a rabbit amino terminal Bcr antibody (against amino acids [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The patient underwent splenectomy in September 2000 and primary cultures of a spleen tissue sample from the patient were established by placing the sample in tissue culture for 2 weeks using RPMI medium supplemented with 10% fetal bovine serum, 200 ng/ml G-CSF, 250 unit/ml GM-CSF and 50 ng/ml SCF. Cells vigorously expanded in the culture and were harvested for Western blotting studies with various antibodies (Figure 1c RT-PCR analyses were conducted to determine whether the 170 kDa Tel-Abl protein originated from a Tel-Abl transcript. Multiplex PCR revealed c-BCR transcripts in typical amounts but no Bcr-Abl transcripts with junctions of e1a2, b2a2, b3a2 and e19a2 were detected using 35 cycle or two cycles of nested PCR (results not shown). Transcripts of c-ABL were detected in high amounts as measured by competitive PCR (2.8 × 10 5 transcripts/g of RNA). These data indicated that no BCR-ABL fusion transcripts were present in patient cells. Experiments were conducted with TEL primers: TEL 1 (nucleotides 1-TCCTGATCTCTCTCGCTGTGA-21), TEL161 (nucleotides 161-ACTCGATCCGCCTGCCTGCG-180), TEL541 (nucleotides 541-CCTCCCACCATTGAACTGTT-560) and TEL 701 (nucleotides 701-AGAACAACCACCAGGAGTCC-720). All the above TEL primers were paired with either an ABL exon 2 (5ЈTCAGACCCTG AGGCTCAAAGTC3Ј) or exon 3 (5ЈGGTACCAGGAGTGTTTCTCCAG (Figure 2a, lane 1) . Thus, the TEL-ABL transcript from the patient described in our study had additional TEL sequences that are 3Ј to that of the TEL sequences in the TEL-ABL transcript from the Ba/F3 cell clone. Moreover, since the TEL 701 and ABL2 primer set yielded an amplimer from the patient, it seems likely that the junction in the patient is a TEL exon 5-ABL exon 2 (T5A2) junction.
Our studies also detected a second TEL-ABL junction in the patient cells when we performed nested (two cycle) PCR (Figure 2b ). When 30 cycles were used ( Figure 2a, lane 2) , a single amplimer band was detected, which is consistent with T5A2 junction. When a nested set of two cycles was performed, two major amplimers were detected ( Figure 2b, lane 2) . One was consistent with the T5A2 junction and the other had the T4A2 junction. To confirm and extend these results, Leukemia PCR products corresponding to these two junctions were extracted from the gel, and the DNA was purified and sequenced by the MDACC DNA sequencing core facility (Figure 2c ). The sequence data for the most abundant junction (T5A2) yielded the expected sequence of a T5A2 junction. The less abundant junction yielded the sequence for T4A2 junction. These results establish that the patient blood cells contain a major authentic TEL-ABL transcript (T5A2 junction) and a minor T4A2 (Figure 2c ).
STI-571 is a potent inhibitor of the Abl tyrosine kinase. STI-571 is currently in clinical trials for treatment of chronic myeloid leukemia and has been found to induce cytogenetic remissions in 33% of chronic myeloid leukemia patients in a phase I trial. Spleen cells were treated with 5 M and 10 M STI-571 for 4 h. Lysates were immunoblotted with anti-phosphotyrosine (Figure 3a) and anti-Abl (not shown). STI-571 strongly inhibited the Tel-Abl tyrosine kinase; inhibition was calculated to be more than 60% (Figure 3c ), using actin protein as a means to control for protein loading (Figure 3b) , and the level of the Bcr-Abl protein as measured by anti-Abl Western blotting (not shown). An identical T5A2 TEL-ABL junction was detected in a patient with sustained granulocytosis who was diagnosed as having typical CML but lacking the BCR-ABL junction. 6 In this study patient cells contained a t(12,14) (p12,q11-3) as the sole chromosomal abnormality, which was determined by fluorescence in situ hybridization (FISH). FISH studies showed a cryptic insertion of ETV6 (TEL) located at 12p12 into ABL at chromosome band 9q34. The ETV6/ABL fusion was confirmed by RT-PCR and sequencing of the junction. Exon 5 of ETV6 was fused in frame to exon 2 of ABL. Recently, another study was reported showing the presence of two TEL-ABL transcripts in a CML and a T cell ALL patient. In this case, they also detected both T5A2 and T4A2 junctions. e1a2, b2a2, b3a2 and e19a2 BCR-ABL transcripts, ruling out the presence of typical BCR-ABL fusions. Cells from this patient were found to express high levels of c-BCR and c-ABL transcripts. Importantly, cytogenetics and FISH analyses failed to detect BCR-ABL fusions. We conclude from these results that the patient has a TEL-ABL fusion with a junction at TEL exon 5 to ABL exon 2. Of interest, a second TEL-ABL transcript with T4A2 was detected in the patient but at very low levels, since it required nested PCR for detection. STI-571, an Abl tyrosine kinase inhibitor, strongly inhibited the tyrosine phosphorylation of the Tel-Abl protein. TO THE EDITOR ALL is the most common leukaemia in childhood and together with nervous system tumours it is the main type of childhood neoplasm. 1 Despite numerous etiological studies, the established risk factors of childhood ALL are few and they account for a small fraction of all cases. According to Little, 1 'factors generally accepted as associated' with leukaemia in childhood include ataxia telangiectasia, Fanconi's anaemia, neurofibromatosis 1, certain types of hereditary immunodeficiency, Down syndrome and, according to earlier studies, intrauterine exposure to X-rays. Remarkably, all but the last factor are genetic conditions. Malignant ALL cells contain diverse clonally expanded gene fusions that are thought to be the initiating event in leukaemogeneis. 2 Infections or the ensuing aberrant immune responses are other risk factors for ALL, which, together with other environmental events, precipitate the disease. 2, 3 Data on twin studies have been controversial or difficult to interpret due to possible selection. 1 In a recent Nordic twin study on 90 000 twins, only two pairs each of monozygotic and dizygotic twins concordant for any type of leukaemia at any age were recorded. 4 Parental leukaemia has not been associated with childhood ALL but leukaemia in a sibling has been a risk factor for leukaemia in other siblings. 1 Because of lack of population-based data on familial risk factors of childhood ALL, we examine here these relationships using the nationwide Swedish Family-Cancer Database including all Swedes, 'offspring' born since 1932 with their parents recorded at birth. The parental population can assume any age in the Database but ALL in the offspring population was considered between ages 0 and 19 years. The Database has been updated in 2001 to include over 10 million individuals and over 1 million malignancies notified to the Swedish Cancer Registry between 1958 and 1998. In addition to familial relationships and neoplasms, the Database contains information on residential area and socio-economic status. Familial risks were calculated for offspring separately for families where only a parent or only a sibling was affected with any malignancy. There were no families where a parent and two siblings were affected by ALL. Standardized incidence ratios (SIRs) were calculated by dividing the observed numbers (O) of cases by the expected (E) ones, calculated as person-years at risk based on age (5-year age-groups)-, period (5- area of residence (two categories)-, socio-economic status (four categories)-and sex-specific incidence rates for all persons in the Database. 5 Confidence intervals (95% CI) were calculated assuming a Poisson distribution. 95% CIs for siblings were adjusted for dependence. 5 In the Family-Cancer Database the annual number of ALL cases, diagnosed before the age of 20 years, has ranged from 60 to 80, with some increase towards the end of the period. These numbers refer to 1975-1998 when uniform ALL diagnoses were recorded at the Swedish Cancer Registry. The total number of affected offspring, diagnosed before the age of 20 years, was 2176. In 2171 families at least one offspring was diagnosed with ALL.
Familial risks for offspring ALL are shown in Table 1 by any malignancy in a family member. ALL was diagnosed in no parent-offspring pairs but five sibling pairs were affected, giving a significant SIR of 7.07. When inspecting the birth years of the affected siblings, three pairs were found to be female twins of unknown zygosity. They showed a vastly increased SIR of 137.61, compared to that of singletons of 2.92, non-significant. A total of 34 families were identified where at least one twin presented with ALL. The twin sisters were born to different families in 1978, 1980 and 1981; in the first family, the twins were diagnosed for ALL at ages 4 and 7 years, in the second family at 4 and 5 years, and in the third family both at 3 years. The affected singleton siblings were both of different sexes. The mother's age at birth was in the 20s in all but two births by a mother who was 38 and 44 years at birth, risk ages for Down syndrome. None of the parents or the other 13 siblings in these families were diagnosed with cancer. The only parental cancer that was associated with ALL in offspring was testicular cancer in a father with an SIR of 2.72 (95% CI 1.08-5.10).
The present study was population-based covering families in all of Sweden. Among the 2171 families with at least one childhood case of ALL, five had two affected offspring and three of these were samesexed twins from 34 affected twin families. The probandwise concordance was 15%. These data support the previous evidence on the foetal origin of childhood ALL 2 but cannot rule out recessive and polygenic modes of inheritance. 4, 5 The excessive risk experienced by the samesexed, possibly monozygotic twins is consistent with the hypothesis that the initial transforming event takes place in one twin whose cells metastasise to the co-twin. 2 Concordance among monozygotic twins, many of whom share the placenta, would be expected to be high.
